Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, USA.
Nat Protoc. 2015 Dec;10(12):1897-903. doi: 10.1038/nprot.2015.118. Epub 2015 Oct 29.
This protocol describes a method for the direct silylation of the carbon-hydrogen (C-H) bond of aromatic heterocycles using inexpensive and abundant potassium tert-butoxide (KOt-Bu) as the catalyst. This catalytic cross-dehydrogenative coupling of simple hydrosilanes and various electron-rich aromatic heterocycles enables the synthesis of valuable silylated heteroarenes. The products thus obtained can be used as versatile intermediates, which facilitate the divergent synthesis of pharmaceutically relevant compound libraries from a single Si-containing building block. Moreover, a variety of complex Si-containing motifs, such as those produced by this protocol, are being actively investigated as next-generation therapeutic agents, because they can have improved pharmacokinetic properties compared with the original all-carbon drug molecules. Current competing methods for C-H bond silylation tend to be incompatible with functionalities, such as Lewis-basic heterocycles, that are often found in pharmaceutical substances; this leaves de novo synthesis as the principal strategy for preparation of the target sila-drug analog. Moreover, competing methods tend to be limited in the scope of hydrosilane that can be used, which restricts the breadth of silicon-containing small molecules that can be accessed. The approach outlined in this protocol enables the chemoselective and regioselective late-stage silylation of small heterocycles, including drugs and drug derivatives, with a broad array of hydrosilanes in the absence of precious metal catalysts, stoichiometric reagents, sacrificial hydrogen acceptors or high temperatures. Moreover, H2 is the only by-product generated. The procedure normally requires 48-75 h to be completed.
本方案描述了一种使用廉价且丰富的叔丁醇钾 (KOt-Bu) 作为催化剂,直接对芳杂环的碳-氢键 (C-H) 进行硅烷化的方法。该方法通过简单的硅烷与各种富电子芳杂环之间的交叉脱氢偶联,实现了有价值的硅烷化杂芳烃的合成。由此得到的产物可用作多功能中间体,可从单个含硅构建块出发,发散式合成具有药物相关性的化合物库。此外,各种复杂的含硅基序,如本方案中生成的硅基序,正被积极用作下一代治疗剂,因为它们与原始的全碳药物分子相比,可能具有改善的药代动力学性质。目前用于 C-H 键硅烷化的竞争方法往往与Lewis 碱性杂环等官能团不兼容,这些官能团通常存在于药物物质中;这使得从头合成成为制备目标硅烷药物类似物的主要策略。此外,竞争方法往往受到可使用的硅烷种类的限制,这限制了可获得的含硅小分子的范围。本方案中概述的方法可在无贵金属催化剂、化学计量试剂、牺牲氢受体或高温的情况下,对包括药物和药物衍生物在内的小杂环进行化学选择性和区域选择性的后期硅烷化,所用的硅烷种类繁多。此外,唯一的副产物是氢气。该过程通常需要 48-75 小时才能完成。